Revision history of "PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT" (Q2035314)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

10 October 2024

22 March 2024

11 June 2023

26 April 2023

8 April 2023

5 July 2022

  • curprev 05:2205:22, 5 July 2022DG Regio talk contribs 39,034 bytes +23,932 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,

12 February 2022

8 February 2022

7 February 2022

24 January 2022

24 December 2021

23 December 2021

16 December 2021

2 November 2020

16 July 2020

8 June 2020

24 March 2020

23 March 2020

  • curprev 09:0109:01, 23 March 2020DG Regio talk contribs 9,076 bytes +638 Created claim: summary (P836): THE PROJECT IS PROPOSED FOR THE PRE-CLINICAL CHARACTERISATION OF THE MEN1611, A NEW P3K INHIBITOR WHICH HAS THE CAPACITY TO BLOCK, IN A PREFERENTIAL MANNER, THE ALPHA, WILD, AND THE RANGE WHICH HAVE CHANGED. THE MOLECULAR DETERMINANTS OF AWARENESS WILL BE STUDIED., Adding English summary

20 March 2020

17 March 2020

12 March 2020

6 March 2020